LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer Meeting Abstract
| Authors: | Oliveira, M.; de Azambuja, E.; Saura, C.; Dubsky, P.; Zardavas, D.; Fesl, C.; Bardia, A.; Soberino, J.; Gil, E. C.; Ng, V.; Fredrickson, J.; Stout, T. J.; Singel, S. M.; Hsu, J. Y.; Piccart, M.; Gnant, M.; Baselga, J. |
| Abstract Title: | LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer |
| Meeting Title: | 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 76 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2015 Dec 8-12 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2016-02-15 |
| Language: | English |
| ACCESSION: | WOS:000375622402022 |
| DOI: | 10.1158/1538-7445.sabcs15-ot1-03-06 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: OT1-03-06 -- Source: Wos |
